Efficacy and adherence of sublingual immunotherapy in patients aged 60 to 75years old with house dust mite-induced allergic rhinitis.

Abstract

This study aimed to evaluate the efficacy and adherence of sublingual immunotherapy (SLIT) for house dust mite (HDM)-induced allergic rhinitis (AR) patients over 60years old. Eighty-six AR patients aged 60-75years old were randomly divided in the control and treatment group as 1:1 ratio. The control group was treated with standard pharmacotherapy while the treatment group was treated with SLIT plus pharmacotherapy on demand. Patients adherence, combined symptom and medication score (CSMS), visual analog scale (VAS), and presence of adverse events were evaluated in the baseline and after 6-months, 12-months and 24-months treatment. Twenty-five (58.1%) subjects in the treatment group and 20 (46.5%) subjects in the control group completed the study (P>0.05). The major reasons for premature cessation were out of touch and relieved symptoms. At the same time, CSMS and VAS of the patients over 60years old in both groups significantly decreased from baseline to any post-baseline time point (all P<0.05). The comparison of CSMS and VAS between the two groups revealed statistically significant differences in favor of the SLIT group at month 24 (P<0.05), whereas no differences at month 6 and month 12 (all P>0.05). 41.9% of the patients dropped out within 2years of SLIT treatment and the major reasons for premature cessation were out of touch and relieved symptoms. This study suggested that SLIT plus pharmacotherapy provided a greater clinical benefit than pharmacotherapy alone at two years.